# BMP3

## Overview
BMP3, or bone morphogenetic protein 3, is a gene that encodes a protein belonging to the transforming growth factor-beta (TGF-β) superfamily, which is known for its regulatory roles in cellular growth and differentiation. The BMP3 protein, also referred to as Osteogenin, is characterized by its cysteine knot motif, a structural feature that is crucial for its stability and function (Carreira2014Bone; Hinck2016Structural). Unlike other members of the BMP family that promote bone formation, BMP3 functions primarily as a negative regulator of bone density by antagonizing the osteogenic effects of other BMPs, such as BMP2, through its interaction with type II activin receptors (Allendorph2007BMP-3; Daluiski2001Bone). This unique role in bone metabolism highlights its potential therapeutic applications in conditions like osteoporosis. Additionally, BMP3 has been implicated in cancer pathogenesis, particularly in colorectal cancer, where its inactivation through promoter hypermethylation suggests a tumor suppressor function (Wen2019BMP3; Loh2008Bone).

## Structure
BMP3, also known as Osteogenin, is a member of the TGF-β superfamily and exhibits a complex molecular structure. The primary structure of BMP3 consists of a polypeptide chain with a characteristic cysteine knot motif, which is crucial for its stability and function (Carreira2014Bone; Hinck2016Structural). The secondary structure includes alpha-helices and beta-sheets, forming a classic TGF-β family architecture with a cystine knot motif, four beta strands, and a conserved R-helix H3 (Allendorph2007BMP-3).

In terms of tertiary structure, BMP3 is stabilized by intramolecular disulfide bridges, which are formed by its seven conserved cysteine residues (Carreira2014Bone). The protein typically forms a covalently linked dimer, representing its quaternary structure, with two monomers connected by an inter-subunit disulfide bond, creating a butterfly shape (Allendorph2007BMP-3). The dimerization is essential for its biological activity and is a common feature among BMPs (Hinck2016Structural).

Post-translational modifications of BMP3 may include glycosylation, which enhances its stability and half-life (Carreira2014Bone). The protein's structure allows it to interact specifically with type II receptors, such as ActRII and ActRIIb, with distinct binding affinities (Allendorph2007BMP-3).

## Function
Bone morphogenetic protein 3 (BMP3) is a member of the TGF-β superfamily and functions primarily as a negative regulator of bone density. Unlike other BMPs, BMP3 does not promote osteogenesis; instead, it antagonizes the osteogenic effects of BMP2 by inhibiting the differentiation of osteoprogenitor cells into osteoblasts. This antagonistic action is mediated through activin receptors, particularly ActRIIb, to which BMP3 binds with high affinity (Allendorph2007BMP-3; Daluiski2001Bone).

BMP3's role in bone metabolism involves the modulation of signaling pathways. It competes with other BMPs for Smad-4, thereby inhibiting osteogenic activities and promoting mesenchymal stem cell proliferation and differentiation into adipocytes (Yang2014Bone). BMP3 activates the TGF-β/activin signaling pathway, specifically through the phosphorylation of Smad2, which is crucial for its role in promoting mesenchymal stem cell proliferation (Stewart2010BMP‐3).

In terms of organismal outcomes, BMP3's inhibition of osteogenesis results in the regulation of bone density, as evidenced by increased trabecular bone density in Bmp3 knockout mice (Daluiski2001Bone). This regulatory function suggests potential therapeutic applications in conditions like osteoporosis.

## Clinical Significance
BMP3 (bone morphogenetic protein 3) has been implicated in several diseases and conditions due to alterations in its expression or function. In bone health, BMP3 acts as a negative regulator of bone density. Studies on Bmp3 knockout mice have shown increased bone density, suggesting that BMP3's antagonistic role in bone formation could have therapeutic implications for osteoporosis (Daluiski2001Bone). 

In the context of cancer, BMP3 is frequently inactivated in colorectal cancer (CRC) through promoter hypermethylation, leading to its downregulation. This inactivation is an early and frequent event in CRC development, suggesting BMP3's role as a tumor suppressor. The reintroduction of BMP3 in CRC cell lines has been shown to suppress tumor growth, indicating its potential as a therapeutic target (Wen2019BMP3; Loh2008Bone). BMP3's hypermethylation status is also being explored as a biomarker for CRC screening (Rokni2018BMP3).

Additionally, BMP3 polymorphisms have been associated with papillary thyroid cancer (PTC), particularly in relation to tumor invasion and progression, highlighting its clinical significance in cancer (KIM2012Polymorphisms). These findings underscore the importance of BMP3 in both bone density regulation and cancer pathogenesis.

## Interactions
BMP3 interacts with several proteins, primarily through its binding to type II activin receptors, particularly ActRIIb, with which it has a significantly higher affinity compared to ActRII (Allendorph2007BMP-3). This interaction is crucial for BMP3's role as an inhibitor of activin and BMP signaling pathways. BMP3 binds to ActRIIB, a receptor shared by both activin and BMP pathways, and this binding is not significantly displaced by activin, suggesting distinct binding sites on ActRIIB for BMP3 and activin (Gamer2005BMP-3). BMP3 can also form a receptor complex with ActRIIB and the type I activin receptor, Alk4, which is suggested to be inactive, thereby preventing activin signal transduction (Gamer2005BMP-3).

BMP3's interaction with ActRIIb involves specific amino acids, such as Ser-28 and Asp-33, which contribute to its unique receptor specificity. Mutations in these residues can increase BMP3's affinity for both ActRII and ActRIIb, indicating their role in modulating binding affinity (Allendorph2007BMP-3). BMP3's binding to ActRIIb is also characterized by a specific interaction between Lys-30 of BMP3 and Glu-76 of ActRIIb, which is crucial for its receptor specificity (Allendorph2007BMP-3).


## References


[1. (Carreira2014Bone) A.C. Carreira, F.H. Lojudice, E. Halcsik, R.D. Navarro, M.C. Sogayar, and J.M. Granjeiro. Bone morphogenetic proteins: facts, challenges, and future perspectives. Journal of Dental Research, 93(4):335–345, January 2014. URL: http://dx.doi.org/10.1177/0022034513518561, doi:10.1177/0022034513518561. This article has 263 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1177/0022034513518561)

[2. (Stewart2010BMP‐3) Aaron Stewart, Haiyan Guan, and Kaiping Yang. Bmp‐3 promotes mesenchymal stem cell proliferation through the tgf‐β/activin signaling pathway. Journal of Cellular Physiology, 223(3):658–666, February 2010. URL: http://dx.doi.org/10.1002/jcp.22064, doi:10.1002/jcp.22064. This article has 76 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.22064)

[3. (Yang2014Bone) Jian Yang, Pujie Shi, Maolin Tu, Yun Wang, Meng Liu, Fengjiao Fan, and Ming Du. Bone morphogenetic proteins: relationship between molecular structure and their osteogenic activity. Food Science and Human Wellness, 3(3–4):127–135, September 2014. URL: http://dx.doi.org/10.1016/j.fshw.2014.12.002, doi:10.1016/j.fshw.2014.12.002. This article has 63 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.fshw.2014.12.002)

[4. (Hinck2016Structural) Andrew P. Hinck, Thomas D. Mueller, and Timothy A. Springer. Structural biology and evolution of the tgf-β family. Cold Spring Harbor Perspectives in Biology, 8(12):a022103, September 2016. URL: http://dx.doi.org/10.1101/cshperspect.a022103, doi:10.1101/cshperspect.a022103. This article has 266 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a022103)

[5. (Allendorph2007BMP-3) George P. Allendorph, Michael J. Isaacs, Yasuhiko Kawakami, Juan Carlos Izpisua Belmonte, and Senyon Choe. Bmp-3 and bmp-6 structures illuminate the nature of binding specificity with receptors,. Biochemistry, 46(43):12238–12247, October 2007. URL: http://dx.doi.org/10.1021/bi700907k, doi:10.1021/bi700907k. This article has 139 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi700907k)

[6. (Daluiski2001Bone) Aaron Daluiski, Thomas Engstrand, Matthew E. Bahamonde, Laura W. Gamer, Eric Agius, Sharon L. Stevenson, Karen Cox, Vicki Rosen, and Karen M. Lyons. Bone morphogenetic protein-3 is a negative regulator of bone density. Nature Genetics, 27(1):84–88, January 2001. URL: http://dx.doi.org/10.1038/83810, doi:10.1038/83810. This article has 325 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/83810)

[7. (Gamer2005BMP-3) Laura W. Gamer, John Nove, Michael Levin, and Vicki Rosen. Bmp-3 is a novel inhibitor of both activin and bmp-4 signaling in xenopus embryos. Developmental Biology, 285(1):156–168, September 2005. URL: http://dx.doi.org/10.1016/j.ydbio.2005.06.012, doi:10.1016/j.ydbio.2005.06.012. This article has 64 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ydbio.2005.06.012)

[8. (KIM2012Polymorphisms) YOUNG OCK KIM, IL KI HONG, YOUNG GYU EUN, SEONG-SU NAH, SOOJEONG LEE, SU-HAK HEO, HYUNG-KEE KIM, HO-YEON SONG, and HAK-JAE KIM. Polymorphisms in bone morphogenetic protein 3 and the risk of papillary thyroid cancer. Oncology Letters, 5(1):336–340, October 2012. URL: http://dx.doi.org/10.3892/ol.2012.962, doi:10.3892/ol.2012.962. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2012.962)

[9. (Wen2019BMP3) Jialing Wen, Xianglin Liu, Yan Qi, Feng Niu, Zhitong Niu, Wenjing Geng, Zhaowei Zou, Renli Huang, Jianping Wang, and Hongzhi Zou. Bmp3 suppresses colon tumorigenesis via actriib/smad2-dependent and tak1/jnk signaling pathways. Journal of Experimental &amp; Clinical Cancer Research, October 2019. URL: http://dx.doi.org/10.1186/s13046-019-1435-1, doi:10.1186/s13046-019-1435-1. This article has 31 citations.](https://doi.org/10.1186/s13046-019-1435-1)

[10. (Loh2008Bone) Kim Loh, June A. Chia, Sonia Greco, Sarah‐Jane Cozzi, Ron L. Buttenshaw, Catherine E. Bond, Lisa A. Simms, Tanya Pike, Joanne P. Young, Jeremy R. Jass, Kevin J. Spring, Barbara A. Leggett, and Vicki L. J. Whitehall. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes, Chromosomes and Cancer, 47(6):449–460, February 2008. URL: http://dx.doi.org/10.1002/gcc.20552, doi:10.1002/gcc.20552. This article has 73 citations.](https://doi.org/10.1002/gcc.20552)

[11. (Rokni2018BMP3) Parisa Rokni, Afsaneh Mojtabanezhad Shariatpanahi, Ebrahim Sakhinia, and Mohammad Amin Kerachian. Bmp3 promoter hypermethylation in plasma-derived cell-free dna in colorectal cancer patients. Genes &amp; Genomics, 40(4):423–428, January 2018. URL: http://dx.doi.org/10.1007/s13258-017-0644-2, doi:10.1007/s13258-017-0644-2. This article has 32 citations.](https://doi.org/10.1007/s13258-017-0644-2)